{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:18:25Z","timestamp":1700601505526},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1038\/bmt.2008.109","type":"journal-article","created":{"date-parts":[[2008,8,22]],"date-time":"2008-08-22T16:10:40Z","timestamp":1219421440000},"page":"S28-S34","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current status of autologous hematopoietic stem cell transplantation in myeloma"],"prefix":"10.1038","volume":"42","author":[{"given":"J","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,13]]},"reference":[{"key":"BFbmt2008109_CR1","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822\u2013824.","journal-title":"Lancet"},{"key":"BFbmt2008109_CR2","unstructured":"Singhal S . High-dose therapy and autologous transplantation. In: Mehta J, Singhal S (eds). Myeloma, Martin Dunitz: London, 2002, pp 327\u2013347."},{"key":"BFbmt2008109_CR3","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","volume":"67","author":"B Barlogie","year":"1986","unstructured":"Barlogie B, Hall R, Zander A, Dicke K, Alexanian R . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298\u20131301.","journal-title":"Blood"},{"key":"BFbmt2008109_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.bmt.1705000","volume":"36","author":"B Sirohi","year":"2005","unstructured":"Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant 2005; 36: 19\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/sj.bmt.1705799","volume":"40","author":"J Mehta","year":"2007","unstructured":"Mehta J, Singhal S . High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101\u20131114.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR6","unstructured":"Powles R, Sirohi B, Treleaven J, Singhal S, Kulkarni S, Lal R et al. Continued first complete remission in multiple myeloma for over 10 years: a series of \u2018operationally cured\u2019 patients. Blood (ASH Annual Meeting Abstracts) 2000; 96: Abstract 2215."},{"key":"BFbmt2008109_CR7","first-page":"166a","volume":"98","author":"R Powles","year":"2001","unstructured":"Powles R, Singhal S, Sirohi B, Horton C, Treleaven J, Mehta J . \u2018Discontinuous complete remission\u2019: a new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods of time. Blood (ASH Annual Meeting Abstracts) 2001; 98: 166a.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFbmt2008109_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","volume":"135","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158\u2013164.","journal-title":"Br J Haematol"},{"key":"BFbmt2008109_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Siegel","year":"1999","unstructured":"Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants multiple myeloma. Blood 1999; 93: 51\u201354.","journal-title":"Blood"},{"key":"BFbmt2008109_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/sj.bmt.1702188","volume":"25","author":"B Sirohi","year":"2000","unstructured":"Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533\u2013539.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2008109_CR12","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt2008109_CR13","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"A Palumbo","year":"2004","unstructured":"Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50\u201370: results of a randomized controlled trial. Blood 2004; 104: 3052\u20133057.","journal-title":"Blood"},{"key":"BFbmt2008109_CR14","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","volume":"106","author":"J Blad\u00e9","year":"2005","unstructured":"Blad\u00e9 J, Rosi\u00f1ol L, Sureda A, Ribera JM, D\u00edaz-Mediavilla J, Garc\u00eda-Lara\u00f1a J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755\u20133759.","journal-title":"Blood"},{"key":"BFbmt2008109_CR15","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","volume":"23","author":"JP Fermand","year":"2005","unstructured":"Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55\u201365 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227\u20139233.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008109_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.bmt.1700917","volume":"20","author":"R Powles","year":"1997","unstructured":"Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435\u2013443.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.bmt.1702167","volume":"25","author":"KR Desikan","year":"2000","unstructured":"Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000; 25: 483\u2013487.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200\u2009mg\/m2 melphalan and 8\u2009Gy total body irradiation plus 140\u2009mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial. Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BFbmt2008109_CR19","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131\u20133136.","journal-title":"Blood"},{"key":"BFbmt2008109_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929\u2013936.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008109_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bmj.327.7415.575","volume":"327","author":"S Singhal","year":"2003","unstructured":"Singhal S . Treatment of multiple myeloma. BMJ 2003; 327: 575\u2013576.","journal-title":"BMJ"},{"key":"BFbmt2008109_CR22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55\u201365.","journal-title":"Blood"},{"key":"BFbmt2008109_CR23","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BFbmt2008109_CR24","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434\u20132441.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008109_CR25","unstructured":"Fermand JP . MAG studies (1985\u20132005). 10th International Myeloma Workshop, Sydney, April 2005 Accessed 2 December 2006. http:\/\/myeloma.org\/pdfs\/Sydney2005_Fermand_P8.pdf."},{"key":"BFbmt2008109_CR26","unstructured":"Goldschmidt H . Single vs double HDT in multiple myeloma: third analysis of the trial GMMG-HD2. 10th International Myeloma Workshop, Sydney, April 2005. Accessed 2 December 2006. http:\/\/myeloma.org\/pdfs\/Sydney2005_Goldschmidt_P8.pdf."},{"key":"BFbmt2008109_CR27","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","volume":"101","author":"CM Segeren","year":"2003","unstructured":"Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144\u20132151.","journal-title":"Blood"},{"key":"BFbmt2008109_CR28","doi-asserted-by":"crossref","unstructured":"Sonneveld P, van der Holt B, Vellenga E, Croockewit S, Verhoef G, Segeren C et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2545.","DOI":"10.1182\/blood.V106.11.2545.2545"},{"key":"BFbmt2008109_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/sj.bmt.1701208","volume":"21","author":"J Mehta","year":"1998","unstructured":"Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887\u2013892.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR30","unstructured":"Sirohi B, Powles R, Mehta J, Kulkarni S, Sankpal S, Treleaven J et al. Prognostic factors at the time of single autotransplantation in 451 myeloma patients treated with 200\u2009mg\/m2 melphalan: results equivalent to tadem autotransplantation. Blood (ASH Annual Meeting Abstracts) 2002; 100: Abstract 673."},{"key":"BFbmt2008109_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bmt.1703717","volume":"30","author":"S Singhal","year":"2002","unstructured":"Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J . Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673\u2013679.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/sj.bmt.1703682","volume":"30","author":"R Powles","year":"2002","unstructured":"Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an \u2018operational cure\u2019? Bone Marrow Transplant 2002; 30: 479\u2013484.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/sj.bmt.1704633","volume":"34","author":"S Kumar","year":"2004","unstructured":"Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004; 34: 485\u2013490.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008109_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR . Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431\u2013436.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008109_CR35","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2215\/CJN.03060906","volume":"1","author":"S Singhal","year":"2006","unstructured":"Singhal S, Mehta J . Multiple myeloma. Clin J Am Soc Nephrol 2006; 1: 1322\u20131330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFbmt2008109_CR36","doi-asserted-by":"crossref","unstructured":"Kumar S, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, Zeldenrust S et al. Analysis of outcome after autologous stem transplantation in patients with newly diagnosed myeloma: comparison of different induction regimens. Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 3079.","DOI":"10.1182\/blood.V108.11.3079.3079"},{"key":"BFbmt2008109_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021\u20131030.","journal-title":"N Engl J Med"},{"key":"BFbmt2008109_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","volume":"102","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495\u2013502.","journal-title":"Br J Haematol"},{"key":"BFbmt2008109_CR39","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565\u20131571.","journal-title":"N Engl J Med"},{"key":"BFbmt2008109_CR40","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289\u20133294.","journal-title":"Blood"},{"key":"BFbmt2008109_CR41","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008109_CR42","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1200\/JCO.1997.15.7.2659","volume":"15","author":"G Tricot","year":"1997","unstructured":"Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659\u20132666.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008109_CR43","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","volume":"95","author":"R Desikan","year":"2000","unstructured":"Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008\u20134010.","journal-title":"Blood"},{"key":"BFbmt2008109_CR44","doi-asserted-by":"crossref","unstructured":"Crowley JJ, McCoy J, LeBlanc M, Barlogie B . Extreme regression: a statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from intergroup trial S9321. Blood (ASH Annual Meeting Abstracts) 2004; 102: Abstract 5202.","DOI":"10.1182\/blood.V104.11.5202.5202"},{"key":"BFbmt2008109_CR45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.V98.2.492","volume":"98","author":"B Barlogie","year":"2001","unstructured":"Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492\u2013494.","journal-title":"Blood"},{"key":"BFbmt2008109_CR46","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609\u20132617.","journal-title":"N Engl J Med"},{"key":"BFbmt2008109_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11864-007-0011-7","volume":"8","author":"S Singhal","year":"2007","unstructured":"Singhal S, Mehta J . Lenalidomide in myeloma. Curr Treatment Options Oncol 2007; 8: 154\u2013163.","journal-title":"Curr Treatment Options Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2008109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008109","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T10:11:35Z","timestamp":1648030295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2008109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":47,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["BFbmt2008109"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2008.109","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"13 August 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}